Design of a novel multiepitope vaccine against glioblastoma by in silico approaches
Abstract Glioblastoma (GBM) is the most common malignant primary brain tumor, with a median survival rate of less than two years. Currently, there is no cure for GBM, underscoring the urgent need for innovative treatment approaches. Vaccine design emerges as a crucial strategy, offering a safe and e...
Saved in:
| Main Authors: | Sako Mirzaie, Kevin Da Yuan, Heyu Ni, Xiao Yu Wu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-03672-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Design and development of highly conserved, HLA-promiscuous T cell multiepitope vaccines against human visceral leishmaniasis
by: Aline Silva Barreto, et al.
Published: (2025-03-01) -
Indicators of the fibrinolytic system in the blood and cerebrospinal fluid of patients with metastatic brain lesions
by: L. A. Goroshinskaya, et al.
Published: (2025-03-01) -
Effect of Plasma Soluble Urokinase-Type Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 Levels in the Plasma of Babylon Women with Breast Cancer
by: Sheerin H. Abbas, et al.
Published: (2025-01-01) -
Proteolytic enzyme and adiponectin receptors as potential targets for COVID-19 therapy
by: K. A. Rubina, et al.
Published: (2021-05-01) -
Can serum soluble urokinase plasminogen activator receptor be an effective biomarker in comparing the inflammatory response between laparoscopic and open appendectomy?
by: Basak Erginel, et al.
Published: (2023-06-01)